COVIDSeq Assay (96 samples)

This low- to mid-throughput NGS assay enables labs of any size to identify and track the emergence and prevalence of novel SARS-CoV-2 variants.

Overview

COVIDSEQ Assay (96 samples) is a comprehensive amplicon-based next-generation sequencing (NGS) assay designed to help research labs identify novel SARS-CoV-2 variants. 

  • Detects genome of SARS-CoV-2 RNA using ARTIC v5.4.2 primers

  • Supports a seamless and flexible end-to-end workflow

Rapid, cost-effective sequencing

Designed to run a low number of samples, the COVIDSeq Assay (96 samples) offers a low-throughput configuration ideal for Illumina benchtop sequencing systems, enabling smaller labs to perform decentralized surveillance of new variants.

Uniform genome coverage

96 amplicons provide full coverage across SARS-CoV-2 genome for in-depth characterization of new variants

Integrated solution

Kit includes all reagents for cDNA conversion, amplification, and library prep. A 63°C annealing temperature during PCR improves variant analysis and insights.

Streamlined data analysis

Assess lineage and annotate mutations with open software tools, including the DRAGEN Microbial Amplicon App in BaseSpace Sequence Hub.

Specifications

Required products

Showing 1 - 1 / 1 Results

FAQs

Showing 1 - 3 / 3 Results

NovaSeq X Series ordering

Advanced chemistry, optics, and informatics combine to deliver exceptional sequencing speed and data quality, outstanding throughput, and scalability.

MiSeq Reagent Kit v3

Optimized reagent kit that provides increased cluster density and read length, improving sequencing quality scores compared to earlier versions.

TruSight Oncology 500

Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.

Illumina DNA Prep

A fast, integrated workflow for preparing libraries for use in a wide range of sequencing applications.

Speak with a specialist

Reach out for information about our products and services, or get answers to questions about our technology.